HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan

Files in This Item:
CurrMedResOpin32_749.pdf271.54 kBPDFView/Open
Please use this identifier to cite or link to this item:http://hdl.handle.net/2115/64956

Title: A randomized, double-blind, placebo-controlled study of escitalopram in patients with social anxiety disorder in Japan
Authors: Asakura, Satoshi Browse this author
Hayano, Taiji Browse this author
Hagino, Atsushi Browse this author
Koyama, Tsukasa Browse this author →KAKEN DB
Keywords: Escitalopram
Japan
Liebowitz Social Anxiety Scale Japanese version (LSAS-J)
Randomized placebo-controlled study
Social anxiety disorder (SAD)
Issue Date: 2016
Publisher: Taylor & Francis
Journal Title: Current medical research and opinion
Volume: 32
Issue: 4
Start Page: 749
End Page: 757
Publisher DOI: 10.1185/03007995.2016.1146663
PMID: 26808688
Abstract: Objective: This randomised, double-blind placebo-controlled study compared the efficacy and tolerability of escitalopram (10 and 20mg/day) in Japanese patients with social anxiety disorder (SAD). Research design and methods: Patients aged 18-64 years with a primary diagnosis of DSM-IV-TR defined SAD, a Liebowitz Social Anxiety Scale Japanese version (LSAS-J) total score ≥60 and a Clinical Global Impression-Severity (CGI-S) score ≥4 at baseline were randomly assigned (1:1:1) to placebo, escitalopram 10mg or 20mg. The primary endpoint was change from baseline to Week 12 in the LSAS-J total score for both escitalopram 10mg and 20mg versus placebo (ANCOVA, FAS, LOCF), using a hierarchical testing procedure. Pre-specified secondary endpoints included LSAS-J sensitivity analyses. Clinical trial registration: This study has the www.japic.or.jp identifier: JapicCTI-121842. Results: For the primary efficacy endpoint, the difference from placebo in the LSAS-J was -3.9 (p=0.089) for escitalopram 10mg. Since the superiority of escitalopram 10mg over placebo was not confirmed, an analysis without multiplicity adjustment was made, which showed a difference for escitalopram 20mg versus placebo of -9.8 (p<0.001). In pre-specified sensitivity analyses, the difference versus placebo was -4.9 (p=0.035) (ANCOVA, FAS, OC) and -5.0 (p=0.028) (MMRM, FAS) (escitalopram 10mg) and -10.1 (p<0.001) (ANCOVA, FAS, OC) and -10.6 (p<0.001) (MMRM, FAS) (escitalopram 20mg). Common adverse events (incidence ≥5% and significantly different from placebo) were somnolence, nausea and ejaculation disorder. Conclusion: Escitalopram was efficacious, safe and well tolerated by patients with SAD in Japan. Study limitations are discussed including patient characteristics.
Rights: This is an Accepted Manuscript of an article published by Taylor & Francis in Current Medical Research and Opinion in 2016, available online: http://www.tandfonline.com/10.1185/03007995.2016.1146663.
Type: article (author version)
URI: http://hdl.handle.net/2115/64956
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 朝倉 聡

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

Feedback - Hokkaido University